Estimated annual percentage changes in age-standardized rates of DALYs and ASDR of IHD attributable to HSBP in asthma across 21 regions from 1990 to 2021. by Zhenhua Zhuang (11192745)

Subjects:

The DALYs, deaths, and their estimated annual percentage changes of ischemic heart disease attributable to high systolic blood pressure from 1990 to 2021. by Zhenhua Zhuang (11192745)

Subjects:

National age-standardized rates of DALYs and ASDR of IHD attributable to HSBP and their estimated annual percentage changes in 2021. by Zhenhua Zhuang (11192745)

Subjects:

The rates of DALYs and deaths of ischemic heart disease attributable to high systolic blood pressure in 2021. by Zhenhua Zhuang (11192745)

Subjects:

Global burden of IHD attributable to HSBP from 1990 to 2021. by Zhenhua Zhuang (11192745)

Subjects:

SDI-based age-standardized rates of DALYs and ASDR for IHD attributable to HSBP. by Zhenhua Zhuang (11192745)

Subjects:

The 2021 Age-standardised rate of DALYs and deaths for ischemic heart disease attributable to high systolic blood pressure in 204 countries and territories. by Zhenhua Zhuang (11192745)

Subjects:

Microhardness vs. depth diagram of sample No. 6 ( by Van-Thuc Nguyen (19469762)

“…The Travel speed factor appears to have the greatest effect, followed by the gas flow rate and current intensity. …”

Table_2_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.xlsx by Kristin R. Anderson (5478734)

Image_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.jpg by Kristin R. Anderson (5478734)

Table_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.pdf by Kristin R. Anderson (5478734)

Flowchart of the screening process. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Result of the AMSTAR-2 assessments. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Characteristics of included reviews. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Result of the PRISMA assessments. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Result of the ROBIS assessments. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Cohort characteristics. by Vincent Pey (21433304)

“…</p><p>Results</p><p>Upon initiation of CPB we observed a significant decrease in arterial whole blood redox potential (101.90 mV + /- 11.52 vs. 41.80 mV + /- 10,26; p < 0.0001). …”

Study selection criteria. by Filip Stanicic (17808254)

“…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”

PICOS criteria for the SLR. by Filip Stanicic (17808254)

“…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”

PRISMA flow chart. by Filip Stanicic (17808254)

“…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”